Quest Diagnostics Inc (DGX) Stock Price Today
Aura AI Summary
Key Stats
- $25.94BMarket Cap
- 799,642Volume
- HealthSector
- $247.4552W High
- $173.4952W Low
- 57 DaysTypical Hold Time
- $31.69BEnterprise Value
- 1.46%Div Yield
- -Trading Activity
Track Quest Diagnostics Inc (DGX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Quest Diagnostics Inc has traded between a low of $173.49 and a high of $247.45, highlighting its annual price range. Buy and sell Quest Diagnostics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Most Recent News
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Silence Therapeutics jumps 125% after $1.3B acquisition deal with Merck KGaA
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.